Neetal Nevrekar, MD

CRS:

BJMC

Role:

Clinical

Position:

Research Clinician

Email:

drneetal24@gmail.com

Dr. Neetal Nevrekar is a research clinician at BJMC-CRS in Pune, India, where she has worked since June 2010. She is experienced in the field of clinical research on HIV, and works on various IMPAACT and ACTG Network research protocols. She worked on research protocols A5207, A5253, and A5225 as a research officer. Presently working on protocols 1077BF and 1077FF (PROMISE), A5282, A5288, and P1078 as a study clinician. 

She screens and enrolls research participants, is involved in developing the source documents for research protocols, and in completing clinical record forms. She is also responsible for adverse event reporting to RSC/DAIDS and for communications with Clinical Managing Committee (CMC) of the respective protocols eith regard to clinical management issues, toxicities, change of study drugs.

Dr. Nevrekar conducts training programs at the site for research staff, counselors and clinical personnel. She has received training in Good Clinical Practices and also completed web based GCP, HSP training. She was a member of Women’s Health Inter-network Scientific Committee (WHISC) for the IMPAACT and ACTG Network.

Dr. Nevrekar received an undergraduate degree from Grant Medical Institute, Mumbai, and a Doctor of Medicine in Obstetrics and Gynaecology from Grant Medical Institute and Bombay Hospital Research Centre. She worked as a senior medical officer at Bombay Hospital Research Centre for four years. Subsequently she was a consultant in Obstetrics and Gynaecology for six years.

  • “Vaginal delivery in a case of Pregnancy with Cervical Fibroid” - Journal of F.I.G.O, vol.49 no.2, page 77 dated April 1999.
  • “A Quadruplet Pregnancy” - Journal of F.I.G.O, vol.57 no.5, page 439-441 dated Sept-Oct. 2007.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More